• Users Online: 1013
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2022  |  Volume : 24  |  Issue : 2  |  Page : 63-70

Beta-lactam beta-lactamase inhibitors

Department Microbiology, Manipal Hospital, New Delhi, India

Correspondence Address:
Sangeeta Joshi
94, Dhaula Kuan Part 1, Delhi Cantt. New Delhi - 110 010
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jacm.jacm_21_22

Rights and Permissions

Four new β lactam-β lactamase inhibitor (BL-BLI) combinations, namely ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and imipenem-cilastatin-relebactam are currently approved by the Food and Drug Administration for complicated urinary tract infections (cUTIs), complicated intra-abdominal infections (cIAIs) and two of them for hospital-acquired pneumonia/ventilator-associated pneumonia. The clinical trials of these antibiotics have shown them to be non-inferior to comparator antibiotics. These antibiotics have action against extended-spectrum beta-lactamase enterobacterales and Klebsiella pneumoniae carbapenemase producers. Some have action against OXA-48 producing Gram-negative bacilli. However, all the above BL-BLI antibiotics have no action against metallo-β lactamase-producing organisms. These are currently being used for the treatment of cUTI and cIAI caused by multidrug-resistant (MDR) Enterobacterales and MDR Pseudomonas aeruginosa.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal